文献速递免疫规划

产气荚膜梭菌ε原型毒素突变体rpETXY30A/Y71A/H106P/Y196A作为抗肠毒血症候选疫苗

Clostridium perfringens epsilon prototoxin mutant rpETXY30A/Y71A/H106P/Y196A as a vaccine candidate against enterotoxemia.
PubMed 文献 · Vaccine · 2023-06-23

研究构建两种重组定点突变体rpETXm41和rpETXm42,在MDCK细胞和小鼠中均无 detectable 毒性;rpETXm41单次和双次接种诱导的IgG滴度和保护水平均高于rpETXm42;绵羊单次接种150 μg rpETXm41后产生持续至少6个月的毒素中和抗体,可抵抗粗制ETX攻击且无微观病变。

要点

  • rpETXm41与rpETXm42在MDCK细胞和小鼠中均无可检测毒性,安全性足以作为候选疫苗。
  • rpETXm41单次和双次接种诱导的小鼠IgG滴度和保护均高于rpETXm42。
  • 绵羊单次接种150 μg rpETXm41后毒素中和抗体持续至少6个月,攻击后无微观病变。

核心结论

  • 遗传脱毒的rpETXY30A/Y71A/H106P/Y196A可作为下一代肠毒血症疫苗的基础。

研究设计与样本

  • 研究合成两种重组定点突变体rpETXm41和rpETXm42,在MDCK细胞和小鼠中评估毒性,在小鼠中比较单次和双次接种的IgG滴度和保护,并进一步在绵羊中测试rpETXm41。

主要发现

  • 与重组pETX(rpETX)相比,rpETXm41和rpETXm42在MDCK细胞和小鼠中均无可检测毒性。
  • rpETXm41和rpETXm42均可与抗粗制ETX的多克隆抗体反应。
  • rpETXm41单次和双次接种诱导的小鼠IgG滴度和保护水平均高于rpETXm42。
  • 绵羊单次接种150 μg rpETXm41后产生显著水平的毒素中和抗体,持续至少6个月,可抵抗粗制ETX攻击且无微观病变。

关键数值与推荐

  • 绵羊单次接种剂量为150 μg rpETXm41。
  • 绵羊毒素中和抗体持续至少6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epsilon toxin (ETX) is secreted by Clostridium perfringens (C. perfringens)as a relatively inactive prototoxin (pETX), which is enzymatically activated to ETX by removing carboxy-terminal and amino-terminal peptides. Genetically engineered ETX mutants have been shown to function as potential vaccine candidates in the prevention of the enterotoxemia caused by C. perfringens. In the present study, two recombinant site-directed mutants of pETX, rpETXY30A/Y71A/H106P/Y196A (rpETXm41) and rpETXY30A/H106P/Y196A/F199E (rpETXm42), were synthesized by mutating four essential amino acid residues (Tyr30, Tyr71, His106, Tyr196 or Phe199). Compared to recombinant pETX (rpETX), both rpETXm41 and rpETXm42 lacked the detectable toxicity in MDCK cells and mice, which suggested that both rpETXm41 and rpETXm42 are sufficiently safe to be vaccine candidates. Despite the fact that rpETXm41 and rpETXm42 were reactogenic with polyclonal antibodies against crude ETX, both single- and double-dose vaccination (Vs and Vd, respectively) of rpETXm41 induced a higher level of IgG titer and protection in mice than that of rpETXm42. Therefore, we selected rpETXm41 for the further study. Sheep received Vs of 150 μg rpETXm41 developed significant levels of toxin-neutralizing antibodies persisting for at least 6 months, which conferred protection against crude ETX challenge without microscopic lesions. These data suggest that genetically detoxified rpETXY30A/Y71A/H106P/Y196A could form the basis of a next-generation enterotoxemia vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Du J, Wang T, Xu L, et al. Clostridium perfringens epsilon prototoxin mutant rpETXY30A/Y71A/H106P/Y196A as a vaccine candidate against enterotoxemia. Vaccine. 2023. PMID: 37357076. doi:10.1016/j.vaccine.2023.06.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。